Deutsch English Français

Contact

EP2049691

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2049691

EP2049691 - CROHN DISEASE SUSCEPTIBILITY GENE [Right-click to bookmark this link]
Status	The application has been withdrawn Status updated on 06.08.2010 Database last updated on 16.11.2024
Most recent event Tooltip	06.08.2010	Withdrawal of application	published on 08.09.2010 [2010/36]
Applicant(s)	For all designated states Genizon Biosciences Inc. 880 McCaffrey Street Ville St-Laurent, QC H4T 2C7 / CA
	[2009/17]
Inventor(s)	01 / RAELSON, John Verner c/o GENIZON BIOSCIENCES INC. 880 McCaffrey Street Ville St-laurent, Québec H4T 2C7 / CA
	02 / SCHREIBER, Stefan c/o GENIZON BIOSCIENCES INC. 880 McCaffrey Street Ville St-laurent, Québec H4T 2C7 / CA
	03 / LITTLE, Randall David c/o GENIZON BIOSCIENCES INC. 880 McCaffrey Street Ville St-laurent, Québec H4T 2C7 / CA
	04 / FRANKE, Andre c/o GENIZON BIOSCIENCES INC. 880 McCaffrey Street Ville St-laurent, Québec H4T 2C7 / CA
	05 / HAMPE, Jochen c/o GENIZON BIOSCIENCES INC. 880 McCaffrey Street Ville St-laurent, Québec H4T 2C7 / CA
	06 / KEITH, Tim c/o GENIZON BIOSCIENCES INC. 880 McCaffrey Street Ville St-laurent, Québec H4T 2C7 / CA
	07 / BRUAT, Vanessa c/o GENIZON BIOSCIENCES INC. 880 McCaffrey Street Ville St-laurent, Québec H4T 2C7 / CA
	08 / BELOUCHI, Abdelmajid c/o GENIZON BIOSCIENCES INC. 880 McCaffrey Street Ville St-laurent, Québec H4T 2C7 / CA
	[2009/17]
Representative(s)	Walton, Seán Malcolm Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB
	[N/P]
Former [2009/17]	Walton, Seán Malcolm Mewburn Ellis LLP 33 Gutter Lane London EC2V 8AS / GB
Application number, filing date	07813412.9	26.07.2007
	[2009/17]
	WO2007US74481
Priority number, date	US20060833261P	26.07.2006 Original published format: US 833261 P
	US20060834151P	31.07.2006 Original published format: US 834151 P
	[2009/17]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2008014400
	Date:	31.01.2008
	Language:	EN
	[2008/05]
	Type:	A2 Application without search report
	No.:	EP2049691
	Date:	22.04.2009
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 31.01.2008 takes the place of the publication of the European patent application.
	[2009/17]
Search report(s)	International search report - published on:	US	09.10.2008
	(Supplementary) European search report - dispatched on:	EP	17.05.2010
Classification	IPC:	C12Q1/70, C12Q1/68, A01N43/04, A61K38/00, C12N15/00, C07K1/00, A01N37/18, C07H21/02, C07H21/04	[2009/17]
	CPC:	C12Q1/6883 (EP,US); C12Q2600/106 (EP,US); C12Q2600/136 (EP,US); C12Q2600/156 (EP,US); C12Q2600/158 (EP,US); C12Q2600/16 (EP,US); (+) C12Q2600/172 (EP,US); Y10T436/143333 (EP,US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2009/17]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	Not yet paid
	MK	Not yet paid
	RS	Not yet paid
Title	German:	SUSZEPTIBILITÄTSGEN FÜR MORBUS CROHN	[2009/17]
	English:	CROHN DISEASE SUSCEPTIBILITY GENE	[2009/17]
	French:	GÈNE DE SUSCEPTIBILITÉ À LA MALADIE DE CROHN	[2009/17]
Entry into regional phase	20.02.2009	National basic fee paid
	20.02.2009	Search fee paid
	20.02.2009	Designation fee(s) paid
	20.02.2009	Examination fee paid
Examination procedure	20.02.2009	Examination requested [2009/17]
	08.04.2009	Amendment by applicant (claims and/or description)
	04.08.2010	Application withdrawn by applicant [2010/36]
Fees paid	Renewal fee
	24.07.2009	Renewal fee patent year 03
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[I]US2004076960 (TAYLOR KENT D [US], et al) [I] 1-30 * claims 1-54 *;
		[I] - OGURA YASUNORI ET AL, "A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease", NATURE, NATURE PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1038/35079114, (20010101), vol. 411, no. 6837, ISSN 0028-0836, pages 603 - 606, XP002177309 [I] 1-30 * abstract * DOI: http://dx.doi.org/10.1038/35079114
		[I] - HUGOT JEAN-PIERRE ET AL, "Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease", NATURE, NATURE PUBLISHING GROUP, LONDON, GB LNKD- DOI:10.1038/35079107, (20010101), vol. 411, no. 6837, ISSN 0028-0836, pages 599 - 603, XP002177308 [I] 1-30 * abstract * DOI: http://dx.doi.org/10.1038/35079107
		[A] - PIERIK MARIE ET AL, "Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases", INFLAMMATORY BOWEL DISEASES, WILLAMS AND WILKINS, HAGERSTOWN, MD, US, (20060101), vol. 12, no. 1, ISSN 1078-0998, pages 1 - 8, XP009132498 [A] 1-30 * abstract * * page 6, column 1, paragraph 4 - paragraph l *
		[I] - YAMAZAKI KEIKO ET AL, "Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease", HUMAN MOLECULAR GENETICS, OXFORD UNIVERSITY PRESS, SURREY LNKD- DOI:10.1093/HMG/DDI379, vol. 14, no. 22, ISSN 0964-6906, (20051115), pages 3499 - 3506, (20051013), XP009132501 [I] 1-30 * abstract * DOI: http://dx.doi.org/10.1093/hmg/ddi379
		[A] - SMYTH DEBORAH J ET AL, "A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US LNKD- DOI:10.1038/NG1800, (20060601), vol. 38, no. 6, ISSN 1061-4036, pages 617 - 619, XP009096717 [A] 1-30 * abstract * DOI: http://dx.doi.org/10.1038/ng1800
		[A] - MASCHERETTI SILVIA ET AL, The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease., PHARMACOGENOMICS JUL 2004 LNKD- PUBMED:15212584, VOL. 5, NR. 5, PAGE(S) 479 - 486, (200407), ISSN 1462-2416, XP002579835 [A] 24-29 * abstract * * page 483, column 1, paragraph l - column 2, paragraph 1 *
		[AP] - PERRICONE ET AL, "ATG16L1 Ala197Thr Is Not Associated With Susceptibility to Crohn's Disease or With Phenotype in an Italian Population", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA LNKD- DOI:10.1053/J.GASTRO.2007.11.017, (20071228), vol. 134, no. 1, ISSN 0016-5085, pages 368 - 370, XP022403838 [AP] 1-13,17-23,30 * page 369, column 2, paragraph l * DOI: http://dx.doi.org/10.1053/j.gastro.2007.11.017
		[IP] - HAMPE J ET AL, "A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US LNKD- DOI:10.1038/NG1954, vol. 39, no. 2, ISSN 1061-4036, (20070201), pages 207 - 211, (20061231), XP002521909 [IP] 1-30 * the whole document * DOI: http://dx.doi.org/10.1038/NG1954
	International search	[X]US5474796 (BRENNAN THOMAS M [US]);
		[X]US2003153495 (LICHENSTEIN HENRY S [US], et al);
		[X]US2004053263 (ABREU MARIA T [US], et al);
		[X]US6287605 (MALAMUD DANIEL [US], et al);
		[X] - HO ET AL., ARTHRITIS AND RHEUMATISM, (2005), vol. 52, pages 3596 - 3602, XP008104121 DOI: http://dx.doi.org/10.1002/ART.21393
		[X] - GENBANK, Database accession no. (AAI17338), XP008115435
		[X] - HOVE ET AL., GUT, (2002), vol. 50, pages 206 - 211, XP008104120 DOI: http://dx.doi.org/10.1136/gut.50.2.206
		[Y] - LI J. ET AL., "Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations", HUMAN MOLECULAR GENETICS, (2004), vol. 13, pages 1715 - 1725, XP002440692 DOI: http://dx.doi.org/10.1093/hmg/ddh182

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p